Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases.
10.7499/j.issn.1008-8830.2111064
- Author:
Ying-Chao WANG
1
;
Wei-Chuang DU
1
;
Chu-Yun YIN
1
;
Xue GONG
1
;
Yuan-Fang LI
1
Author Information
1. Department of Children's Hematology and Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Publication Type:Journal Article
- Keywords:
Burkitt's lymphoma;
Child;
Prognosis;
Rituximab
- MeSH:
Adolescent;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Burkitt Lymphoma/pathology*;
Child;
Child, Preschool;
Female;
Humans;
Infant;
Lactate Dehydrogenases;
Male;
Prognosis;
Retrospective Studies;
Rituximab
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(5):561-565
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the clinical features and chemotherapy response of Burkitt's lymphoma (BL) in children and the influence of rituximab on the prognosis of children with BL.
METHODS:A retrospective analysis was performed for the medical data of 62 children with BL, including clinical features, therapeutic efficacy, and prognostic factors. The Cox regression model was used to identify the factors associated with poor prognosis in children with BL. According to whether rituximab was used, the children with advanced (stage III/IV) BL were divided into two groups: chemotherapy plus rituximab and chemotherapy alone. The prognosis was compared between the two groups.
RESULTS:For these 62 children, the median age of onset was 5 years (range 1-14 years), and there were 58 boys (94%) and 4 girls (6%). The primary site was abdominal cavity in 41 children (66%), and head and neck in 16 children (26%). There were 1 child with stage I BL (2%), 8 with stage II BL (13%), 33 with stage III BL (53%), and 20 with stage IV BL (32%). The median follow-up time was 29 months, with progression/recurrence observed in 15 children (24%), and the 3-year overall survival (OS) rate and event-free survival (EFS) rate were 82.8%±5.2% and 77.3%±5.8%, respectively. For the children with stage III/IV BL, there was a significant difference in the 3-year the OS rate between the chemotherapy plus rituximab group (16 children) and the chemotherapy alone group (30 children) (93.3%±6.4% vs 65.6%±9.9%, P=0.042), while there was no significant difference in the 3-year EFS rate between the two groups (86.2%±9.1% vs 61.8%±10.1%, P>0.05). The Cox regression analysis showed that central nervous system involvement, lactate dehydrogenase >1 000 U/L, and early incomplete remission were the factors associated with poor prognosis (P<0.05).
CONCLUSIONS:Chemotherapy combined with rituximab can improve the prognosis of children with stage III/IV BL. Central nervous system involvement, elevated lactate dehydrogenase level, and early incomplete remission may indicate a poor prognosis in children with BL.
